Yang Q, Lu X, Fang Z, Gao Y, He Y, Huang Y
BMC Infect Dis. 2025; 25(1):270.
PMID: 40000979
PMC: 11852542.
DOI: 10.1186/s12879-025-10675-2.
Wangwiwatsin A, Kulwong S, Phuyao C, Titapun A, Loilome W, Klanrit P
Wellcome Open Res. 2025; 10:1.
PMID: 39949572
PMC: 11822251.
DOI: 10.12688/wellcomeopenres.23535.1.
Wen L, Wang B, Zhang H
Front Med (Lausanne). 2025; 11:1515539.
PMID: 39911668
PMC: 11794818.
DOI: 10.3389/fmed.2024.1515539.
Armartmuntree N, Kittirat Y, Promraksa B, Loilome W, Dokduang H, Techasen A
PLoS One. 2025; 20(1):e0317111.
PMID: 39820585
PMC: 11737735.
DOI: 10.1371/journal.pone.0317111.
Sintusen P, Vaeteewoottacharn K, Chaon U, Pairojkul C, Aphivatanasiri C, Suttiprapa S
Sci Rep. 2025; 15(1):436.
PMID: 39747977
PMC: 11696817.
DOI: 10.1038/s41598-024-84444-7.
Impact of ALDH1A1 Expression in Intrahepatic Cholangiocellular Carcinoma.
Kurowski K, Foll M, Werner T, Schilling O, Werner M, Fichtner-Feigl S
J Cancer. 2025; 16(1):1-11.
PMID: 39744576
PMC: 11660125.
DOI: 10.7150/jca.99944.
Comprehensive review on parasitic infections reported in the common fish found in UT of Jammu and Kashmir, India.
Mustafa R, Rather S, Kousar R, Ashraf M, Shah A, Ahmad S
J Parasit Dis. 2024; 48(4):736-761.
PMID: 39493488
PMC: 11528093.
DOI: 10.1007/s12639-024-01697-9.
The Constellation of Risk Factors and Paraneoplastic Syndromes in Cholangiocarcinoma: Integrating the Endocrine Panel Amid Tumour-Related Biology (A Narrative Review).
Ciobica M, Sandulescu B, Chicea L, Iordache M, Groseanu M, Carsote M
Biology (Basel). 2024; 13(9).
PMID: 39336089
PMC: 11429066.
DOI: 10.3390/biology13090662.
Prognostic Values of Ferroptosis-Related Proteins ACSL4, SLC7A11, and CHAC1 in Cholangiocarcinoma.
Amontailak S, Titapun A, Jusakul A, Thanan R, Kimawaha P, Jamnongkan W
Biomedicines. 2024; 12(9).
PMID: 39335604
PMC: 11428419.
DOI: 10.3390/biomedicines12092091.
The Epidemiology of Biliary Tract Cancer and Associated Prevalence of MDM2 Amplification: A Targeted Literature Review.
Kratz J, Klein A, Gray C, Marten A, Vilu H, Knight J
Target Oncol. 2024; 19(6):833-844.
PMID: 39302603
PMC: 11557622.
DOI: 10.1007/s11523-024-01086-5.
Cholangiocarcinoma.
Dixon M, Williams M, Pappas S
Cancer Treat Res. 2024; 192:165-184.
PMID: 39212921
DOI: 10.1007/978-3-031-61238-1_9.
Liver Flukes: Clonorchis and Opisthorchis.
Saijuntha W, Sithithaworn P, Wangboon C, Andrews R, Petney T
Adv Exp Med Biol. 2024; 1454:239-284.
PMID: 39008268
DOI: 10.1007/978-3-031-60121-7_7.
Spatial analysis of cholangiocarcinoma in relation to diabetes mellitus and Opisthorchis viverrini infection in Northeast Thailand.
Thinkhamrop K, Suwannatrai K, Kelly M, Suwannatrai A
Sci Rep. 2024; 14(1):10510.
PMID: 38714779
PMC: 11076619.
DOI: 10.1038/s41598-024-61282-1.
Update on the Screening, Diagnosis, and Management of Cholangiocarcinoma.
Kodali S, Connor A, Brombosz E, Ghobrial R
Gastroenterol Hepatol (N Y). 2024; 20(3):151-158.
PMID: 38680168
PMC: 11047158.
Hight prevalent of infection and coincident metacercariae in cyprinid fishes in upper northeastern region of Thailand.
Senasri N, Chumnanka N, Sriyasak P, Suwanpakdee S, Kumla S, Sreeputhorn K
Parasite Epidemiol Control. 2024; 25:e00348.
PMID: 38645674
PMC: 11031773.
DOI: 10.1016/j.parepi.2024.e00348.
Inflammatory responses to infection in animal models: A comparison between susceptible and nonsusceptible hosts in different anatomical locations.
Tangkawattana S, Suyapoh W, Thongrin T, Wendo W, Salao K, Suttiprapa S
Open Vet J. 2024; 14(2):664-673.
PMID: 38549578
PMC: 10970119.
DOI: 10.5455/OVJ.2024.v14.i2.6.
A systematic review of the effects of hepatitis B and C virus on the progression of liver fluke infection to liver cancer.
ORourke A
Trop Dis Travel Med Vaccines. 2024; 10(1):6.
PMID: 38486298
PMC: 10941421.
DOI: 10.1186/s40794-023-00215-8.
Modeling the persistence of Opisthorchis viverrini worm burden after mass-drug administration and education campaigns with systematic adherence.
Kamber L, Burli C, Harbrecht H, Odermatt P, Sayasone S, Chitnis N
PLoS Negl Trop Dis. 2024; 18(2):e0011362.
PMID: 38422118
PMC: 10931503.
DOI: 10.1371/journal.pntd.0011362.
Primary Biliary Tract Cancers in Golestan, Iran: 13-Year Experience of Golestan Population-Based Cancer Registry.
Ashkbari A, Amlashi F, Besharat S, Mofidi M, Amiriani T, Fazel A
Arch Iran Med. 2024; 26(9):504-509.
PMID: 38310406
PMC: 10862055.
DOI: 10.34172/aim.2023.76.
FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy.
Roussot N, Vincent J, Palmier R, Constantin G, Bengrine L, Fumet J
Front Oncol. 2023; 13:1293670.
PMID: 38098503
PMC: 10720590.
DOI: 10.3389/fonc.2023.1293670.